Skip to main content
Premium Trial:

Request an Annual Quote

IP Update: Oct 7, 2010

Premium

Title: siRNA Targeting Survivin

Patent Number: 7,807,819

Filed: Sept. 10, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Through these methodologies, one can select siRNA that target genes, including survivin."


Title: siRNA Targeting Beta Secretase

Patent Number: 7,807,820

Filed: Dec. 11, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to nucleotide sequences for BACE."


Title: Compositions and Methods for Preventing and Treating Presbycusis

Application Number: 20100247530

Filed: March 19, 2010

Lead Inventor: Shinichi Someya, Marine Bio

The invention, the patent application's abstract states, comprises "compositions and methods for preventing and treating presbycusis. In particular, the … invention provides compositions and methods for preventing and treating presbycusis by inhibiting Bak."

The application specifically claims the use of an siRNA to inhibit Bak.


Title: hTERT Gene Expression Regulatory Gene

Application Number: 20100248356

Filed: March 31, 2010

Inventor: Norimasa Miura, Tottori University

The invention, the patent application's abstract states, comprises "a novel substance capable of regulating the expression of a telomerase reverse transcriptase gene in a cell of a mammal. … The expression of a telomerase reverse transcriptase gene can be inhibited by inhibiting the expression of the gene. By utilizing this mechanism, the expression of a telomerase reverse transcriptase gene can be regulated."

The application specifically claims the use of a dsRNA to regulate hTERT.


Title: siRNA Targeting Ribonucleotide Reductase M2 Polypeptide

Application Number: 20100248990

Filed: Aug. 7, 2009

Lead Inventor: Anastasia Khvorova, Dharmacon (Thermo Fisher Scientific)

"Efficient sequence-specific gene silencing is possible through the use of siRNA technology," the patent application's abstract states. "By selecting particular siRNAs by rational design, one can maximize the generation of an effective gene-silencing reagent, as well as methods for silencing genes. Methods, compositions, and kits generated through rational design of siRNAs are disclosed including those directed to RRM2."


Title: dsRNA Compositions and Methods for Treating HPV Infections

Application Number: 20100249052

Filed: March 25, 2008 PCT Filed: March 25, 2008

Lead Inventor: John Benson, Alnylam Pharmaceuticals

"The invention relates to a double-stranded ribonucleic acid for treating human papillomavirus infection," the patent application's abstract states. "The dsRNA comprises an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19 [to] 25 nucleotides in length, and which is substantially complementary to at least a part of an HPV target gene selected from the human E6AP gene.

"The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HPV infection and the expression of the E6AP gene using the pharmaceutical composition; and methods for inhibiting the expression of the HPV target genes in a cell," the abstract adds.


Title: microRNA Signatures in Human Ovarian Cancer

Application Number: 20100249213

Filed: Sept. 8, 2008 PCT Filed: Sept. 8, 2008

Inventor: Carlo Croce, Ohio State University

The invention, the patent application's abstract states, comprises "novel methods and compositions for the diagnosis, prognosis, and treatment of ovarian cancer. The invention also provides methods of identifying anti-cancer agents."


Title: Multiplex Dicer-Substrate RNA Interference Molecules Having Joining Sequences

Application Number: 20100249214

Filed: Feb. 11, 2010

Inventor: Bob Brown, Dicerna Pharmaceuticals

The invention is based, at least in part, "upon the insight that compound [Dicer-substrate siRNA] agents can be generated using site-specific RNase H-cleavable double-stranded nucleic acid regions to attach … one DsiRNA moiety to another DsiRNA moiety, and/or one DsiRNA moiety to a functional group and/or payload," the patent application's abstract states.

"Because such double-stranded nucleic acid joining sequences are site-specifically RNase H-cleavable, the bifunctional molecule is cleaved into DsiRNAs which bear terminal ends that orient dicer cleavage," it adds. "The detrimental impact of administering a single double-stranded nucleic acid RNAi agent of longer than 30 [to] 35 nucleotides in length can be minimized, as once administered or delivered to a subject or RNase H-containing cell, RNase H cleavage produces a shortened, active DsiRNA agent.

"The invention also provides bifunctional DsiRNA agents that are joined by double-stranded DNA extension joining sequences," the abstract notes. "Such bifunctional DsiRNA agents joined by dsDNA sequences do not provoke RNase H cleavage."


Title: Oligomeric Compounds and Compositions for Use in Modulation of Pri-miRNAs

Application Number: 20100249215

Filed: June 10, 2010

Lead Inventor: Bridget Lollo, Regulus Therapeutics

The patent application, its abstract states, claims "compounds, compositions and methods … for modulating the levels, expression, processing, and function of pri-miRNAs. In particular, methods and compounds are provided for the modulation of the levels, expression, processing, or function of polycistronic pri-miRNAs.

"The compositions comprise oligomeric compounds targeted to small non-coding RNAs and pri-miRNAs," it adds. "Further provided are methods for selectively modulating pri-miRNA levels in a cell. Also provided are methods for identifying oligomeric compounds that result in an increase in pri-miRNA levels when contacted with a cell."


Title: Methods for Assessing the Delivery of Exogenous Agents

Application Number: 20100251392

Filed: May 2, 2008

Lead Inventor: Yu Shen, Abbott

"This invention provides methods, compositions and kits for rapid determination of the delivery of exogenous agents both in vitro and in vivo, including without limitation siRNA, microRNA, a ribozyme, or an antisense molecule, any of which may target, bind to, or inactivate the mRNA of the gene of interest expressed in the cells," the patent application's abstract states. "The methods, compositions and kits utilize a promoter-reporter construct whereby successful non-viral nucleic acid delivery leads to an up-regulation of reporter signals thus providing a quantitative, sensitive, and rapid means of detection, validation, and monitoring."

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.